ClinicalTrials.gg
TerminatedNCT04737330ORBITUpdated Apr 15, 2026Results posted

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

A Phase 3 interventional study of Secukinumab and Placebo in Thyroid Eye Disease and Graves Orbitopathy, sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Graves Ophthalmopathy with a site in Germany — none open to participants now, 5 under way, 4 of them phase 3. Graves Ophthalmopathy · Germany.

Enrollment
20th of 20
28 · median 109
Started
2021
with 1 other
Phase 3
16 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
1 of 20
Novartis Pharmaceuticals

Among the 20 studies in Graves Ophthalmopathy with a site in Germany, this one is the 20th largest by enrollment, is one of 2 that started in 2021, is one of 16 in phase 3, and was the 5th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

None of the 20 studies in Graves Ophthalmopathy with a site in Germany is open now. The open studies under Graves Ophthalmopathy, anywhere →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Graves Ophthalmopathy with a site in Germany as a file.
02

Study summary

Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD). Several lines of evidence suggest an important role of interleukin-17A (IL-17A) in the pathogenesis of TED; increased levels of IL-17A have been detected in the serum and tears of patients with TED and IL-17A levels correlate with clinical activity of the disease. T-helper 17 cells (Th17 cells) (as well as other cellular sources of IL-17A, e.g., Tc17 cells) have been shown to infiltrate the orbital tissue of affected patients, producing IL-17A. IL-17A stimulates fibroblast activation, leading to retrobulbar tissue expansion and orbital fibrosis, which causes significant functional impairment. Secukinumab is a recombinant high-affinity fully human monoclonal anti-IL-17A antibody currently approved for the treatment of 3 inflammatory/ autoimmune diseases: moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) (ankylosing spondylitis (AS) and non-radiographic axSpA). The purpose of this study was to demonstrate the efficacy and safety of secukinumab 300 mg subcutaneous (s.c.) in adults with active, moderate to severe TED.

Read the detailed description

This study consisted of the following 3 periods:

  1. Screening period (Week -6 to Baseline):

    Participants' eligibility was assessed during the Screening period, which occurred for a maximum of 6 weeks.

  2. Treatment period (Baseline to Week 16):

    Eligible participants were randomized in a 1:1 ratio to one of the following double-blinded treatment arms:

    • Arm 1: Secukinumab 300 mg s.c. at Baseline, Week 1, 2, 3, 4, 8, 12
    • Arm 2: Placebo s.c. at Baseline, Week 1, 2, 3, 4, 8, 12

    Participants were stratified according to current smoking status (up to 20% smokers per arm) since smoking has a well-known impact on treatment efficacy in TED.

  3. Follow-up/open-label retreatment period (Week 16 up to Week 108):

    • Proptosis responders (see definition below) at Week 16 were followed for relapse up to Week 68. If these participants relapsed, they were offered a course of open-label secukinumab at the time of relapse (see "proptosis relapsers" definition below).
    • Proptosis non-responders (see definition below) at Week 16 were offered the option of open-label secukinumab treatment (with maintenance of blind to initial randomized treatment) for a duration of 16 weeks, i.e., up to Week 32 with last dose at Week 28, as follows:

      • Open-label secukinumab 300 mg s.c. at Week 16, 17, 18, 19, 20, 24 and 28. Thereafter (i.e., from Week 32), participants were followed up for a further 24 weeks to assess the relapse rate.
      • For participants who were proptosis non-responders and who did not receive open-label secukinumab treatment, a follow-up visit 8 weeks after the Week 16 visit needed to be scheduled per protocol. At this follow-up visit, the assessments associated with the Week 24 visit (for responders) were to be performed.
    • Proptosis relapsers (see definition below) during the follow-up period (from Week 16 onward to Week 68) were offered the option of retreatment with open-label secukinumab for a duration of 16 weeks (with maintenance of blind to initial randomized treatment) at the time of relapse as follows:

      • Open-label secukinumab 300 mg s.c. at time of relapse, then at 1, 2, 3, 4, 8 and 12 weeks since time of relapse. Thereafter, participants were followed up for a further 24 weeks (i.e., 40 weeks after start of retreatment) to assess rate of relapse and safety.
      • For participants not receiving open-label secukinumab treatment a follow-up visit 8 weeks after the Week 16 visit were to be scheduled per protocol, if not yet completed. At this follow-up visit, the assessments associated with the Week 24 visit (for responders) were to be performed.

Definitions of proptosis responder, non-responder and relapser:

  • Proptosis responders: Participants achieving response in reduction of proptosis at Week 16 defined as follows: reduction of >= 2 mm from Baseline in the study eye without deterioration (>= 2 mm increase) of proptosis in the fellow eye.
  • Proptosis non-responders: Participants not achieving response in reduction of proptosis at Week 16 with "response" defined as follows: reduction of >= 2 mm from Baseline in the study eye without deterioration (>= 2 mm increase) of proptosis in the fellow eye.
  • Proptosis relapsers: Participants who were "proptosis responders" as defined above, and then relapsed based on proptosis at any time during the 52-week follow-up period with relapse defined as follows: increase in proptosis of >= 2 mm compared to Week 16 in the study eye or deterioration of proptosis (>= 2 mm increase) in the fellow eye at any time during 52-week follow-up period.

In case of worsening of the disease, participants were allowed to receive alternative treatment for TED at the discretion of the investigator and were discontinued from the study treatment.

The primary endpoint analysis was planned to be performed once all participants had reached Week 40, which included the primary efficacy endpoint (Week 16), efficacy of retreatment for initial non-responders and relapse rates during 24 weeks of follow-up.

The final analysis was planned to be performed when the last participant had reached the end of trial.

The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) expressed different preferences regarding the primary and secondary objectives and endpoints and their ordering. Therefore, this study intended to have 2 different analysis strategies and corresponding primary, secondary objective and endpoint definitions; Plan A was intended for submission in Europe (EU) and other applicable countries and Plan B was intended for submission in the United States (US) and other applicable countries. As the study was early terminated, only Plan A analysis was conducted.

03

Conditions studied

  • Thyroid Eye Disease
  • Graves Orbitopathy

Keywords

  • TED
  • Bulging eyes
  • Exophthalmos
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient had to be able to understand and communicate with the investigator and comply with the requirements of the study and had to give a written, signed and dated before any study assessment was performed.
  • Male or non-pregnant, non-lactating female patients ≥ 18 years of age.
  • Clinical diagnosis of active, moderate to severe TED (not sight-threatening) in the study eye at Baseline associated with 2 or more of the following:

    • Lid retraction >= 2 mm
    • Moderate or severe soft tissue involvement
    • Exophthalmos >= 3 mm above normal
    • Inconstant or constant diplopia
  • Onset of TED symptoms fewer than 12 months prior to Baseline.
  • CAS >= 4 (on a 7-point scale, with a score of >= 3 indicating active TED) in the more severely affected (study) eye at Screening and Baseline. Note: Proptosis is the primary qualifier for selection of the study eye. In case both eyes showed a similar degree of proptosis, other inflammatory signs and symptoms (CAS) were taken into account by the investigator for the selection of the study eye.
  • Peripheral euthyroidism or mild hypo-/hyperthyroidism defined as free T3 (fT3) and free T4 (fT4) \< 30% above/below normal limits at Screening. Every effort was to be made to correct the mild hypo-/hyperthyroidism promptly and to maintain the euthyroid state until the end of this study.
  • Orbital MRI assessment available confirming the diagnosis of TED for patients initially presenting with hypo- or euthyroidism (without treatment for hyperthyroidism) before or at the time of TED diagnosis (to rule out other potential causes of orbital signs and symptoms.

Key Exclusion Criteria:

  • Improvement in CAS of >= 2 points and/or improvement in proptosis of >= 2 mm in the study eye between Screening and Baseline.
  • Signs of sight-threatening TED defined by optic neuropathy or severe corneal injury.
  • Patients, in the opinion of the investigator, requiring immediate or urgent medical treatment with for TED.
  • Patients requiring immediate surgical ophthalmological intervention or planning corrective surgery/irradiation during the course of the study.
  • Decreased best corrected visual acuity (BCVA) as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect or color defect within the last 6 months.
  • Any other ophthalmic and/or orbital disease or condition that might interfere with the assessment of TED.
  • Previous orbital radiotherapy.
  • Previous ophthalmological/orbital surgery for TED (e.g., orbital decompression).
  • Previous use of biological agents for the treatment of TED.
  • Previous use of systemic, non-biologic, immunomodulatory agents for the treatment of TED (e.g., mycophenolate or cyclosporine).
  • Previous exposure to secukinumab or other biologic drugs directly targeting IL-17A or the IL 17 receptor (e.g., ixekizumab, brodalumab).
  • Previous treatment with rituximab, tocilizumab or teprotumumab.
  • Previous use of systemic corticosteroids for the treatment of TED, except for oral corticosteroids with a cumulative dose equivalent to \< 1 g oral prednisone/prednisolone if the corticosteroid was discontinued at least 4 weeks prior to Baseline.
  • Previous treatment with any cell-depleting therapies including but not limited to anti-cluster of differentiation 20 (CD20) or agents (e.g., CAMPATH, anti CD4, anti-CD5, anti-CD3, anti-CD19).
  • Use of other investigational drugs within 5 half-lives of enrollment or within 30 days, whichever is longer.
  • Previous or ongoing use of prohibited treatments (see Appendix 16.1.1-Protocol Section 6.2.2). Respective detailed in this section needed to be adhered to.
  • History of to any of the study drug constituents.

Other protocol defined Inclusion/Exclusion may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Secukinumab 300 mg

    Secukinumab 300 mg subcutaneous (s.c.) injection at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12

    Drug: Secukinumab

  • Placebo comparator
    Placebo

    Placebo subcutaneous (s.c.) injection at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12

    Drug: Placebo

Interventions

  • Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12

    Also known as: AIN457

  • DrugPlacebo

    Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12

06

What researchers measure

Primary outcomes

  1. Plan A - Percentage of Participants Achieving Overall Response

    The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in clinical activity score (CAS) AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, purely descriptive analyses were performed for the primary endpoint.

    Time frame: Baseline, Week 16

  2. Plan B - Percentage of Participants Achieving Response in Reduction of Proptosis

    The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the primary endpoint.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Plan A - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)

    The percentage of participants achieving response in reduction of clinical activity score (CAS) at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

    Time frame: Baseline, Week 16

  2. Plan A - Percentage of Participants Achieving Response in Reduction of Proptosis

    The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

    Time frame: Baseline, Week 16

  3. Plan A - Percentage of Participants Achieving Response in Diplopia

    The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

    Time frame: Baseline, Week 16

  4. Plan A - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye

    Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline: * Symptoms * Spontaneous retrobulbar pain * Pain on attempted upward or downward gaze * Signs * Redness of eyelids * Redness of conjunctiva * Swelling of caruncle or plica * Swelling of eyelids * Swelling of conjunctiva (chemosis) For each item present, 1 point is given. The sum of these points is the CAS score, i.e., minimum score of 0 and maximum score of 7. * Inactive TED: CAS \< 3. * Active TED: CAS \>= 3.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  5. Plan A - Mean Change From Baseline to Week 16 in Millimeters (mm) of Proptosis in the Study Eye

    Proptosis measurements were performed at the frequency indicated in the study schedule. The same Hertel instrument, and the same outer intercanthal distance, were to be used for each measurement. The mean of measurements (change from baseline in millimeters (mm) of proptosis, calculated as: (Post-Baseline value - Baseline value) / Baseline value \* 100)) for each group were presented. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  6. Plan A - Percentage of Participants With Improvement in EUGOGO Disease Severity

    Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline. Improvement in EUGOGO disease severity was categorized: Mild, Moderate to severe and Sight threatening.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  7. Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning) Over Time

    The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  8. Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning) Over Time

    The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  9. Plan A - Number of Participants With Adverse Events

    The distribution of adverse events during Plan A study treatment period was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From first dose of study treatment until Week 16

  10. Plan B - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)

    The percentage of participants achieving response in reduction of CAS at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 16

  11. Plan B - Percentage of Participants Achieving Overall Response

    The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in CAS AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 16

  12. Plan B - Percentage of Participants Achieving Response in Diplopia

    The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 16

  13. Plan B - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye.

    Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 16

  14. Plan B - Mean Change From Baseline to Week 16 in Proptosis in the Study Eye.

    Proptosis is the protrusion of the eyeball. Exophthalmos means the same, and this term is usually used when describing proptosis due to Grave's disease. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 16

  15. Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning)

    The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  16. Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning)

    The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  17. Plan B - Number of Participants With Adverse Events

    Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

    Time frame: From first dose of study treatment until Week 16

07

Results

Posted Jan 9, 2025

Participant flow

This study was conducted at 5 centers in Germany.

Treatment Period (Baseline to Week 16)
Participant flow — Treatment Period (Baseline to Week 16)
MilestoneSecukinumab 300 mgPlacebo
Started1414
Completed1212
Not completed22
Withdrew: Lost to follow-up10
Withdrew: Study terminated by sponsor12
Follow-up Period (Week 16 to Week 108)
Participant flow — Follow-up Period (Week 16 to Week 108)
MilestoneSecukinumab 300 mgPlacebo
Started1212
Completed89
Not completed43
Withdrew: Not satisfied10
Withdrew: Study terminated by sponsor31
Withdrew: No benefit imp01
Withdrew: Therapy national guidelines01

Outcome measures

PrimaryPlan A - Percentage of Participants Achieving Overall Response

The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in clinical activity score (CAS) AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, purely descriptive analyses were performed for the primary endpoint.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Plan A - Percentage of Participants Achieving Overall Response
ParticipantsSecukinumab 300 mgPlacebo
Yes00
No1211
Missing23
PrimaryPlan B - Percentage of Participants Achieving Response in Reduction of Proptosis

The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the primary endpoint.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryPlan A - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)

The percentage of participants achieving response in reduction of clinical activity score (CAS) at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Plan A - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)
ParticipantsSecukinumab 300 mgPlacebo
Yes03
No128
Missing23
SecondaryPlan A - Percentage of Participants Achieving Response in Reduction of Proptosis

The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Plan A - Percentage of Participants Achieving Response in Reduction of Proptosis
ParticipantsSecukinumab 300 mgPlacebo
Yes00
No1211
Missing23
SecondaryPlan A - Percentage of Participants Achieving Response in Diplopia

The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Plan A - Percentage of Participants Achieving Response in Diplopia
ParticipantsSecukinumab 300 mgPlacebo
Yes11
No1111
Missing22
SecondaryPlan A - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye

Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline: * Symptoms * Spontaneous retrobulbar pain * Pain on attempted upward or downward gaze * Signs * Redness of eyelids * Redness of conjunctiva * Swelling of caruncle or plica * Swelling of eyelids * Swelling of conjunctiva (chemosis) For each item present, 1 point is given. The sum of these points is the CAS score, i.e., minimum score of 0 and maximum score of 7. * Inactive TED: CAS \< 3. * Active TED: CAS \>= 3.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Mean · Unit on a scale
Plan A - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye
Unit on a scaleSecukinumab 300 mgPlacebo
Change from BL at Week 2-0.21 ± 0.58-0.29 ± 0.47
Change from BL at Week 4-0.14 ± 1.10-0.29 ± 0.73
Change from BL at Week 80.00 ± 1.00-0.21 ± 0.58
Change from BL at Week 12-0.67 ± 1.15-0.57 ± 0.94
Change from BL at Week 160.00 ± 0.95-0.73 ± 1.10
SecondaryPlan A - Mean Change From Baseline to Week 16 in Millimeters (mm) of Proptosis in the Study Eye

Proptosis measurements were performed at the frequency indicated in the study schedule. The same Hertel instrument, and the same outer intercanthal distance, were to be used for each measurement. The mean of measurements (change from baseline in millimeters (mm) of proptosis, calculated as: (Post-Baseline value - Baseline value) / Baseline value \* 100)) for each group were presented. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Mean · millimeters (mm)
Plan A - Mean Change From Baseline to Week 16 in Millimeters (mm) of Proptosis in the Study Eye
millimeters (mm)Secukinumab 300 mgPlacebo
Change from BL at Week 20.18 ± 0.72-0.07 ± 0.73
Change from BL at Week 40.18 ± 0.720.00 ± 1.18
Change from BL at Week 80.42 ± 1.000.43 ± 1.28
Change from BL at Week 120.67 ± 0.980.29 ± 1.33
Change from BL at Week 160.83 ± 1.030.64 ± 1.03
SecondaryPlan A - Percentage of Participants With Improvement in EUGOGO Disease Severity

Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline. Improvement in EUGOGO disease severity was categorized: Mild, Moderate to severe and Sight threatening.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Count of participants · Participants
Plan A - Percentage of Participants With Improvement in EUGOGO Disease Severity
ParticipantsSecukinumab 300 mgPlacebo
Baseline — Mild00
Baseline — Moderate to severe1414
Baseline — Sight threatening00
Week 2 — Mild00
Week 2 — Moderate to severe1414
Week 2 — Sight threatening00
Week 4 — Mild11
Week 4 — Moderate to severe1312
Week 4 — Sight threatening00
Week 8 — Mild01
Week 8 — Moderate to severe1313
Week 8 — Sight threatening00
Week 12 — Mild11
Week 12 — Moderate to severe1113
Week 12 — Sight threatening00
Week 16 — Mild11
Week 16 — Moderate to severe1110
Week 16 — Sight threatening00
SecondaryPlan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning) Over Time

The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Mean · Unit on a scale
Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning) Over Time
Unit on a scaleSecukinumab 300 mgPlacebo
Baseline64.1 ± 23.0466.6 ± 24.38
Week 262.9 ± 27.7166.4 ± 20.51
Week 456.7 ± 28.1166.7 ± 23.82
Week 851.0 ± 27.9359.1 ± 24.75
Week 1254.7 ± 29.4560.8 ± 28.71
Week 1652.1 ± 29.3661.9 ± 30.42
SecondaryPlan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning) Over Time

The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Mean · Unit on a scale
Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning) Over Time
Unit on a scaleSecukinumab 300 mgPlacebo
Baseline65.6 ± 22.4360.3 ± 20.60
Week 268.3 ± 16.1662.5 ± 29.42
Week 469.2 ± 21.0156.7 ± 30.37
Week 865.4 ± 20.5152.2 ± 30.87
Week 1263.5 ± 26.0953.1 ± 34.47
Week 1666.2 ± 26.8456.8 ± 30.55
SecondaryPlan A - Number of Participants With Adverse Events

The distribution of adverse events during Plan A study treatment period was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.

Time frame:
From first dose of study treatment until Week 16
Reported as:
Count of participants · Participants
Plan A - Number of Participants With Adverse Events
ParticipantsSecukinumab 300 mgPlacebo
Any adverse event (AE)96
Study treatment related AE31
AE leading to study treatment discontinuation00
Serious adverse event (SAE)01
Study treatment related SAE00
SAE leading to study treatment discontinuation00
SecondaryPlan B - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)

The percentage of participants achieving response in reduction of CAS at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Percentage of Participants Achieving Overall Response

The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in CAS AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Percentage of Participants Achieving Response in Diplopia

The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye.

Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Mean Change From Baseline to Week 16 in Proptosis in the Study Eye.

Proptosis is the protrusion of the eyeball. Exophthalmos means the same, and this term is usually used when describing proptosis due to Grave's disease. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning)

The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning)

The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryPlan B - Number of Participants With Adverse Events

Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.

Time frame:
From first dose of study treatment until Week 16

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events are presented for the double-blind treatment period (from first dose of study treatment until Week 16) and for the follow-up/open-label re-treatment period, including AEs in follow up for all patients who received at least one dose of Secukinumab during the entire study up to a maximum of 108 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg (Double-blind)0/14 (0%)1/14 (7.1%)12/14 (85.7%)
Placebo (Double-blind)0/14 (0%)1/14 (7.1%)12/14 (85.7%)
Any Secukinumab 300 mg (Entire Study)0/26 (0%)1/26 (3.8%)23/26 (88.5%)
Most frequent serious events
Most frequent serious events
EventSecukinumab 300 mg (Double-blind)Placebo (Double-blind)Any Secukinumab 300 mg (Entire Study)
Graves' diseaseEndocrine disorders1/140/141/26
Endocrine ophthalmopathyEye disorders0/141/140/26
Most frequent other events
Showing 10 of 56
Most frequent other events
EventSecukinumab 300 mg (Double-blind)Placebo (Double-blind)Any Secukinumab 300 mg (Entire Study)
COVID-19Infections and infestations4/146/1410/26
Urinary tract infectionInfections and infestations0/143/142/26
HeadacheNervous system disorders3/142/145/26
FatigueGeneral disorders2/140/142/26
ArthralgiaMusculoskeletal and connective tissue disorders2/140/142/26
HypertensionVascular disorders1/142/143/26
LymphadenopathyBlood and lymphatic system disorders1/140/141/26
NeutropeniaBlood and lymphatic system disorders1/140/141/26
VertigoEar and labyrinth disorders1/140/141/26
Thyroid dermatopathyEndocrine disorders0/141/141/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Secukinumab 300 mgPlaceboTotal
Mean53.6 ± 11.8557.7 ± 10.6455.6 ± 11.25
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mgPlaceboTotal
Female91221
Male527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 300 mgPlaceboTotal
White141428
Smoking History
Smoking History(Participants)Secukinumab 300 mgPlaceboTotal
Current347
Former8614
Never347
08

Study locations

5 sites
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60318, Germany
  • Novartis Investigative Site
    Freiburg im Breisgau, 79106, Germany
  • Novartis Investigative Site
    Göttingen, 37075, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in May 2023, 17 months.

Results were first posted in Jan 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Feb 3, 2021
StartActual
Nov 29, 2021
Primary completionActual
May 16, 2023
CompletionActual
May 16, 2023
Results first posted
Jan 9, 2025
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04737330
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Nov 29, 2021
Primary completion
May 16, 2023
Completion
May 16, 2023
Results posted
Jan 9, 2025
Last update
Apr 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion